Overview

• RES-010 is an antisense oligonucleotide that blocks miR-22 to reprogram metabolism rather than suppress appetite.
• In mice, weekly injections produced weight loss without reduced food intake and weight did not rebound after treatment stopped, according to an EASD abstract.
• Non-human primates given RES-010 lost about 15% of fat mass with roughly 1% lean-mass loss over 10 weeks, whereas semaglutide reduced fat by about 16% but cut lean mass by about 8% in reported data.
• Combined dosing with semaglutide and RES-010 led to weight loss that persisted after both drugs were discontinued in animal tests.
• A phase 1 study has been running in the Netherlands since November 2024 with results expected in early 2026, and independent experts caution that conclusions must await full, peer-reviewed human data.